Swiss National Bank Has $4.82 Million Stock Holdings in Enovis Co. (NYSE:ENOV)

Swiss National Bank lifted its stake in shares of Enovis Co. (NYSE:ENOV) by 2.5% during the 4th quarter, HoldingsChannel.com reports. The firm owned 109,800 shares of the company’s stock after buying an additional 2,700 shares during the period. Swiss National Bank’s holdings in Enovis were worth $4,818,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Raymond James Financial Inc. acquired a new stake in Enovis during the fourth quarter worth about $16,407,000. Artemis Investment Management LLP boosted its position in shares of Enovis by 35.4% during the 4th quarter. Artemis Investment Management LLP now owns 665,868 shares of the company’s stock worth $29,218,000 after acquiring an additional 174,116 shares in the last quarter. DAVENPORT & Co LLC increased its stake in Enovis by 6.0% in the fourth quarter. DAVENPORT & Co LLC now owns 2,782,341 shares of the company’s stock valued at $121,181,000 after acquiring an additional 157,216 shares during the last quarter. Tributary Capital Management LLC raised its position in Enovis by 33.9% during the fourth quarter. Tributary Capital Management LLC now owns 566,089 shares of the company’s stock valued at $24,840,000 after purchasing an additional 143,258 shares in the last quarter. Finally, Stephens Inc. AR bought a new stake in Enovis during the fourth quarter worth $3,740,000. Institutional investors own 98.45% of the company’s stock.

Enovis Price Performance

ENOV stock opened at $40.01 on Tuesday. Enovis Co. has a 1 year low of $35.14 and a 1 year high of $62.79. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12. The stock has a market cap of $2.28 billion, a price-to-earnings ratio of -18.27 and a beta of 2.05. The company has a 50 day simple moving average of $42.61 and a 200 day simple moving average of $43.47.

Enovis (NYSE:ENOV) last announced its quarterly earnings results on Wednesday, February 26th. The company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.92 by $0.06. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The company had revenue of $560.98 million during the quarter, compared to analysts’ expectations of $555.14 million. Research analysts anticipate that Enovis Co. will post 2.79 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Needham & Company LLC lowered their price target on Enovis from $65.00 to $64.00 and set a “buy” rating for the company in a report on Thursday, February 27th.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.